Alzheon to Present Clinical, Imaging, and Fluid Biomarker Results from Trials with Oral Valiltramiprosate/ALZ-801 at 2026 AD/PD Conference in Copenhagen, Denmark
Valiltramiprosate Shows Promise as an Oral Potentially Disease-Modifying Agent that can Slow Alzheimer’s Disease Based on Clinical Results,…